Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore’s S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara

This article was originally published in The Pink Sheet Daily

Executive Summary

The multi-kinase inhibitor might have stalled after S*BIO focused on funding its first two candidates in the clinic, CEO says. The company is still involved in preclinical development.

You may also be interested in...



Singapore S*BIO Inks "One Of The Biggest" Biotech Deals in Asia With Onyx For JAK2 Inhibitors

PERTH, Australia - Singapore-based S*BIO inked a development collaboration and option and license agreement with Onyx Pharmaceuticals for S*BIO's two JAK2 inhibitors SB1518 and SB1578, S*BIO announced Jan. 6

S*BIO CEO Jan-Anders Karlsson On Development Success In Singapore: An Interview With PharmAsia News

Founded in 2000 as a joint venture between Chiron and the Economic Development Board of Singapore, S*BIO was one of the first biotech companies in Singapore. The company's pipeline consists of novel targeted small molecule drugs for the treatment of cancer with leading programs around histonedeacetylases and kinases. S*BIO announced Oct. 20 completion of a $26 million Series-B financing led by Bio*One Capital and Aravis Venture, which will allow the company to more forward into Phase II clinical development of its two lead oncology compounds. S*BIO CEO Jan-Anders Karlsson recently sat down with PharmAsia News' Australia bureau to discuss its pipeline and operations out of Singapore.

Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China

Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel